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Abstract
We present a fatal case of the end-stage renal disease complication that is calciphylaxis. Also known as calcific uremic 
arteriolopathy, it is characterised by vascular calcification, necrosis of the skin and adipose tissue, and constant severe 
pain of the affected areas.
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Introduction
Calciphylaxis, also known as calcific uremic arteriolopathy 
(CUA), is a rare disease with an estimated annual incidence 
ranging from 1 to 35 in every 10,000 haemodialysed pa-
tients worldwide [1]. Its pathogenesis in unclear. Calciphyla-
xis affects small vessels of the skin and fatty tissue, as cal-
cium deposits accumulate within their walls. This, together 
with thrombotic occlusion, leads to ischaemic necrosis of 
the skin that causes severe pain within the affected areas 
[1, 2]. Typical clinical manifestation of the disease includes 
extremely painful skin lesions, starting as tender red areas 
and often later transforming into eschars, ulcerations or 
gangrene, most commonly located on the patient’s legs. 
The distal pattern involves extremities below the knee and 
elbow joints, and the proximal pattern involves the areas of 
the inner thighs, buttocks and abdomen [2]. Calciphylaxis 
is most commonly associated with end-stage renal disease 
(ESRD), although non-uremic calciphylaxis has been 
observed in patients with primary hyperparathyroidism, 
some cancers (treated with chemotherapy), liver cirrhosis, 
and autoimmune diseases. Risk factors of calciphylaxis 
include, among others, haemodialysis, female sex, obesi-
ty, diabetes mellitus, Caucasian ethnicity, hypercalcemia, 
hyperphosphatemia, hyperparathyroidism (both primary 
and secondary), adynamic bone disease, elevated al-
kaline phosphatase, autoimmune diseases, hypoalbu-
minemia, genetic polymorphisms, abnormalities within 
the coagulation system, recurring skin trauma (e.g. from 
subcutaneous injections) and medications (e.g. warfarin, 
calcium, vitamin D, iron, and recombinant PTH) [1, 3, 4]. 
Calciphylaxis is associated with high mortality: more than 
50% of patients die within a year of diagnosis, with sepsis 
as the main cause of death [2, 4].
Case report
A 64-year-old obese woman, suffering from insulin-de-
pendent diabetes, arterial hypertension, ischaemic heart 
disease, atherosclerosis and ESRD (on haemodialysis), was 
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Due to an increased CRP, wounds were swabbed. Methi-
cillin-susceptible S. aureus (MSSA), A. baumannii and 
C. parapsilosis were found. Therapy comprising ciprofloxa-
cin, vancomycin and ceftriaxone was initiated. Haemodialy-
sis was conducted daily, but due to oral mucosal bleeding, 
heparin was discontinued (coagulation parameters were 
within limits). A pain management consultation was made: 
morphine and paracetamol therapy was initiated, and lat-
er changed to buprenorphine. Due to anaemia, a total of 
9 units of packed red blood cell were transfused. Cinacal-
cet was used to treat hyperparathyroidism. The patient’s 
general state was slowly deteriorating: she was somnolent, 
limbs were oedematous, necrotic areas were enlarging, and 
liquefactive necrosis of the left hand appeared. A surgical 
consultation was made and the patient was preliminarily 
qualified for left upper limb amputation. Vascular disorder 
was treated with apixaban, and sodium thiosulfate was 
ordered, although the patient died due to multi-organ dys-
function before this could be received.
Discussion
Calciphylaxis, although uncommon even in high risk groups 
of patients [1], is an important, and potentially fatal, com-
plication of ESRD. This is why doctors should be vigilant 
referred to a vascular surgeon due to a suspicion of rapidly 
progressing atherosclerosis. After surgical consultation, 
she was admitted to hospital due to critical ischaemia 
of fingers and toes and suspected cutaneous necrotising 
vasculitis (Figures 1A, 1B and 2A–D). Physical examination 
revealed generalised oedema, bluish colouring of the skin 
proximally to ischaemic lesions on all extremities, an ampu-
tated left ring finger (up to the middle of proximal phalanx 
— Figures 1A and 1B), haematomas located on the skin of 
the abdomen and lumbosacral region, and restricted limb 
movement. The patient complained of constant severe pain 
in her hands and feet.
Laboratory tests revealed normocytic anaemia [red 
blood cells (RBC) 2.21 M/µL; hameoglobin (Hb) 6.8 g/dL; 
hematocrit (HCT) 21%], heightened inflammatory mar-
kers [white blood cells (WBC) 20.67 K/µL; C-reactive pro-
tein (CRP) 127.63 g/L], hyperparathyroidism [parathor-
mone (PTH) 542 pg/mL, N: 15–65 pg/mL), hypoalbu-
minemia (2.74 g/dL, N: 3.50–5.50 g/dL), hypocalcemia 
(3.55 mEq/L, N: 4.50–5.50 mEq/L), and hyperphosphate-
mia (6.50 mg/dL, N: 2.50–4.80 mg/dL). A skin biopsy was 
performed, but no sign of calcification was found. Chest, 
abdomen and lower and upper limb X-rays were ordered. 
These showed extensive calcification in projections of vis-
ceral arteries and arteries of the limbs (Figures 3 and 4).
Figure 1. Patient’s hands on admission — dorsal (A) and palmar (B) surface
BA
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about it. If a patient presents risk factors for developing 
calciphylaxis, its typical signs, such as painful ischaemic 
skin lesions, should suggest the need for further diagno-
stics, which can be tricky.
In this particular case, the patient had multiple risk 
factors of developing calciphylaxis — she was a Caucasian 
obese woman suffering from diabetes and ESRD (under-
going haemodialysis), with hyperphosphatemia, hypoal-
buminemia and hyperparathyroidism. She also presented 
with typical symptoms — necrosis of the skin and constant 
severe pain. She was consulted by a general practitioner, 
who believed that the lesions were a result of atheroscle-
rosis, and then a vascular surgeon, who ruled out an ath-
erosclerotic basis for the symptoms but did not make an 
alternative diagnosis. The diagnosis was not in fact made 
until after the patient had been admitted to the Nephrol-
ogy Clinic. Even then, the results of additional tests were 
not consistent with the diagnosis. The skin biopsy, which is 
considered the gold standard in the diagnosis of calciphy-
laxis [4, 5], showed no signs of intravascular calcifications. 
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Figure 3. X-ray of both hands. Arrows point out massive calcifications in projections of arteries
Figure 4. X-ray of both feet. Arrows point out massive calcifications in projections of arteries
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Performed X-rays showed continuous calcifications in the 
projections of arteries, but these were misidentified as cal-
cium deposits in atheromatous plaques.
When these symptoms occur, complex and multimo-
dal treatment is necessary, including analgesics, wound 
debridement, use of a hyperbaric chamber, infection pre-
vention, proper nutrition (to prevent malnutrition), and 
the elimination of risk factors. Pharmacological therapy 
involves the use of anticoagulants (the decision is made 
individually considering the risk of bleeding) or intrave-
nous sodium thiosulfate [1, 4, 6]. Sodium thiosulfate is 
often used in treating calciphylaxis [1, 4], but it is not 
available in Poland and must be imported, which is time- 
-consuming and reduces the chances of wound healing 
and overall survival.
Because of its high mortality and limited therapeutic 
options, prevention and early diagnosis are the key ele-
ments of treating calciphylaxis.
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Streszczenie
Przedstawiono śmiertelny przypadek schyłkowej niewydolności nerek powikłanej wystąpieniem kalcyfilaksji — stanu, 
w którym dochodzi do kalcyfikacji w obrębie naczyń, martwicy skóry i tkanki podskórnej oraz stałego silnego bólu w ob-
szarach dotkniętych procesem chorobowym.
Słowa kluczowe: kalcyfilaksja, wapniejąca arteriolopatia mocznicowa, schyłkowa niewydolność nerek, powikłania
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